Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: thymopentin - mondoBIOTECH

Drug Profile

Research programme: thymopentin - mondoBIOTECH

Alternative Names: DasKloster 0112-01; DK-0112; TP 5 - Mondobiotech; TP-5

Latest Information Update: 16 Jul 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator mondoBIOTECH
  • Class Peptides
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sarcoidosis
  • Available For Licensing Yes - Sarcoidosis

Highest Development Phases

  • No development reported Sarcoidosis
  • Discontinued Lung disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Sarcoidosis in Switzerland
  • 09 Mar 2011 Research programme: thymopentin - mondoBIOTECH is available for licensing as of 09 Mar 2011. http://www.mondobiotech.com
  • 04 Feb 2011 Research programme: thymopentin - mondoBIOTECH receives Orphan Drug status for Sarcoidosis in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top